WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review on Recent Trends in Neuropathic Pain Treatment

Sanket Babanrao Kanade*, Chaitali M. Diwane[1]

Student, Pharmacology, SMBT College of Pharmacy, Maharashtra, India*
Assistant professor, pharmacology, SMBT College of Pharmacy, Maharashtra, India[1]
Sanketkanade298@gmail.com, Chaitalidiwane01@gmail.com
DOI : https://doi.org/10.55248/gengpi.6.0125.0314

ABSTRACT:

Over a million individuals globally suffer from neuropathic pain, which is a serious issue. These people have had difficulty since effective therapies are not readily available. The ones we now have frequently have major negative effects and simply treat the symptoms. Furthermore, they may cease to function as a result of individuals growing intolerant of them over time. But in the past 10 years, researchers have made strides in comprehending the mechanisms underlying neuropathic pain. Today, a lot of effort is being put into developing novel medicines that do more than merely mask symptoms. This study examines current medical approaches to treating neuropathic pain. They are investigating techniques such as electrical stimulation of the spine or brain, blockage of nerves, spinal nerve stimulation, and steroid injections. Other more experimental methods include gene therapy and the use of chemicals or light to manipulate nerves. However, because we currently lack the necessary instruments, the majority of these techniques are still in the early phases of testing, making it difficult to integrate them into practical investigations. Nonetheless, if researchers continue towork on these therapies, they may discover fresh approaches to improving the lives of those who from neuropathic pain.

Keywords: Neuropathic pain, effective therapies, Electrical Stimulation, Steroidal Injection.

1. Introduction:

Injury or illness to the somatosensory nerve scheme can outcome in neuropathic pain. This discomfort is produced through a variety of pathogenic causes, and it is frequently classified according to the location inside the body where it occurs or what caused it. Neuropathic pain is frequently caused by metabolic diseases such as peripheral diabetic neuropathy (PDN), nerve problems related through viral contaminations (leprosy, HIV, and post-herpetic neuralgia), and autoimmune diseases impacting the central nervous system (such as numerous sclerosis and Guillain-Barre syndrome), peripheral neuropathies brought on via chemotherapy, nervous system injury brought on by trauma (such for example spinal cord damage and elimination), inflammatory conditions, inherited neuropathies, and channelopathies.

One particularly complex kind of persistent pain is called neuropathic pain. As opposed to other forms of pain, which are primarily caused by tissue injury, it occurs when anything goes wrong with your nerves. Numerous conditions might trigger it, including diabetes, shingles, multiple sclerosis, and certain medications you may be on. Although each person's experience of pain is unique, it is frequently described as searing, shooting, stabbing, or shocking. You may occasionally have increased sensitivity to touch or temperature changes, as well as tingling or numbness in certain body areas(1).

The effects of neuropathic pain can be very debilitating. Imagine having a constant, scorching, stabbing, or electric shock-like pain. It would be constant. This is not the same type of pain as when you break a bone or cut oneself. It's because you're feeling tense for some reason. It is so persistent that it makes daily tasks like going to work, hanging out with friends, or even just engaging in hobbies extremely difficult. Additionally, it disrupts sleep, leaving you exhausted all the time and feeling worse. But it goes beyond the physical. Managing this ongoing pain might seriously damage your mental health. Because no one else really understands what you're going through, you can always feel incredibly depressed or anxious, or you might just feel completely alone. Neuropathic pain is difficult to manage. Ordinary painkillers may not be very effective. To help you manage it, you'll need a large team of medical professionals, including therapists and possibly even surgeons. Finding what works best for you will take time, but if you allow this pain to control you, it may seriously ruin your life(1).

A person's life is severely disrupted by neuropathic pain, which remains very hard to manage. It cannot be solved by taking a medicine. It frequently requires a large team of specialists to assist manage it, not just with medication but also with other forms of therapy. When compared to people without this type of pain, those who experience it typically have relatively low-quality lives. Research indicates that reducing pain has a important impact on an individual's overall excellence of lifetime. However, despite the wide variety of medications available, they are not always effective and can have a number of negative side effects. To attempt and improve things, it's crucial to apply a variety of treatments rather than just medication. The long-term effects of medications and other treatments, such as counselling or physical therapy, on the lives of those who experience this type of pain were the

focus of this study. Physicians shouldbe aware of latest growths in the organisation of neuropathic discomfort. New treatments, operations, and then medications are constantly existence developed. Physicians can provide patients with the greatest and most recent treatments by being aware of these(2).

2. Pathophysiology of Neuropathic Pain:

	Cortical Changes Description	**Peripheral Changes Description**	**Spinal Changes Description**
Sensitisation	Changed down reticence of the brain stem (moderated by the cortex and amygdala) Limbic part initiative nervousness and depression and sleep.	Changes in ion- channels increased activity of sodium channels leading to improved excitability, damage of potassium channels to modulate nerve action	elevated appearance and activity of calcium channels prominent to improved transmitter release and improved excitability of spinal neurons, prolonged receptor fields through NMDA receptor activation A-fibre sprouting into laminae I and II of the dorsal horn, which can result in allodynia
Spontaneous Pain	Ectopic impulse at the thalamus	Ectopic impulses along Aβ, Aδ, and C fibres of neuromas, nerve roots	Ectopic impulses at the dorsal root ganglia

Table 1. Pathophysiology of Neuropathic Pain





(3)

Fig1. Mechanism of Action of Neuropathic Pain

3. Etiology:

Two primary causes of neuropathic pain are either elevated nerve activity (also referred to as sympathetically sustained pain) or a malfunction in nerve signaling (often referred to as deafferentation pain).Neuropathic pain is frequently brought on by damage to or problems with peripheral nerves(4). A few instances are:

a. **Mononeuropathies:** These affect only one nerve and are encountered in situations such as radiculopathy brought on by an expanding intervertebral disk or carpal tunnel syndrome(5).

b. **Plexopathies:** These are usually caused by trauma, inflammation, or nerve compression (e.g., by a tumour) and involve several nerves within a particular neural plexus(6).

c. **Polyneuropathies:** They frequently impact several nerves throughout the body. Numerous conditions, including metabolic diseases, paraproteinemia's, toxic exposures (such alcohol or chemotherapy), genetic predispositions, and, in rare cases, immune-mediated pathways, can be the cause of them(7).

Neuropathic pain has many complex causes, such as changes in:

Peripheral Nociceptor and Nerve Level: Peripheral nerves that are involved in pain perception undergo alterations(8).

Dorsal Root Ganglion: The dorsal root ganglion, a collection of nerve cell bodies connected to spinal nerves, has changed(9).

Central Nervous System (CNS) Nociceptive Pathway and Terminal Structures: Modifications are made to the pathways and end structures of the CNS that are associated with pain perception.

An damage to the nociceptor and peripheral nerve produces inflammation and opens up cation channels, especially sodium channels. These modifications enhance the reactivity to painful stimuli and decrease the activation threshold. The peripheral nerve continuously transmits aberrant pain signals to the central nervous system (CNS) in chronic disorders. Central sensitization is the term for the changes in the receptive nociceptors brought about by this continuous barrage of nociceptive input. These receptors become extremely sensitive in this state, seeing even small stimuli—including non-painful ones, which can cause allodynia—as severe pain. They also believe that this pain is coming from a larger location than it truly is. If there is a break in the constant peripheral nociceptive input, these modifications can be undone, at least momentarily(10).

Somatosensory pathway disruption may contribute to central neuropathic pain syndromes, which are pain related with problems in the central nervous system (CNS). Although any CNS lesion can cause these symptoms, they usually appear more frequently after a stroke, as a result of spinal cord injury, or in conjunction with a demyelinating plaque in multiple sclerosis. If the pain is in the region that is clinically pretentious by the CNS dysfunction, it influence be categorised as central neuropathic discomfort. The improvement of central neuropathic hurt needs a malfunction of the spinothalamic tract, which is in charge of temperature and pinprick perception. That being said, it's not necessary to involve the whole impacted area. It is important to investigate alternative sources of pain if temperature and pinprick sensations are normal in the suspected central neuropathic pain location(11). Musculoskeletal problems are more common in neurologically disabled people. Examples include upper extremity overuse syndrome in wheelchair-bound individuals with spinal cord damage or shoulder pain resulting from arm paralysis following a stroke.

4. Types of Neuropathic Pain:

d. **Diabetic neuropathic pain**: The illness known as diabetic neuropathy is characterised by a loss of sensation that begins in the feet and progresses upward, resulting in discomfort and serious health problems. The International Diabetes Federation estimations that 425 million persons global suffer from diabetes, building it the highest health concern of the twenty-first century. Thirty million personalities in the US, 73 million in India, and 115 million in China are diabetics(12).



Fig 2. Patterns of Nerve Injury in Diabetic Neuropathy.

e. **post-Herpetic neuralgia**: A persistent pain condition that develops three months or longer after shingles is called post-herpetic neuralgia (PHN). The varicella-zoster virus, which normally causes chickenpox, can become latent and then reactivate to produce shingles, also known as acute herpes zoster. PHN is characterised by persistent, occasionally challenging-to- treat nerve discomfort.

f. **Trigeminal neuralgia**: An excruciating, sporadic, one-sided facial pain brought on by light pressure is known as trigeminal neuralgia. It's critical to differentiate it from painful dental conditions. There are two types of TN: secondary TN (STN) and classical TN (CTN)(13).

g. **Central neuropathic pain:** A disease known as central neuropathic pain (CNP) effects from wound to the brain, brainstem, or spinal cord, which remain the sensory pathways that make up the central nervous system (CNS). It is, in short, pain that is not just a result of general dysfunction but also of problems such as CNS lesions or disorders(8).

5. Pharmacological management of neuropathic pain:

		Drugs	**Dose Range**	**Adverse effect**
First-Line therapy	Gabapentinoids	Gabapentin	150-600mg/day	Fatigue, vertigo, peripheral swelling,blured vision
		Pregabalin	300-600mg/day	Fatigue, vertigo, peripheral swelling, improved body load
	Tricyclic antidepressants (TCAs)			Anticholinergic effects, QT prolongation (arrhythmia), suicide risk, urinary retention
		Amitriptyline	10-150mg/day	Vomiting, fatigue, constipation, ataxia, dry mouth
	Serotonin norepinephrine reuptake inhibitors (SNRI)	Duloxetine	20-120mg/day	Vomiting, vertigo, fatigue, hyperhidrosis, high blood pressure
		venlafaxine	150-225mg/day	

Second-Line therapy	Opioids	Tramadol	25-400mg/day	vomiting, constipation, fatigue, seizures, ataxia
		Tapentadol	50-600mg/day	vomiting, constipation, fatigue, seizures, ataxia
	Topical treatment	Lidocaine	5% patches	Local erythema, itching and rash
		capsaicin	8% patches	Discomfort, erythema, itching; rare cases of high blood pressure
Third-Line therapy	Strong opioids	Morphine	10-120mg/day	Vomiting, constipation, vertigo and fatigue
		Oxycodone	10-120mg/day	vomiting, constipation, fatigue, respiratory control
	Neurotoxin	Botulinum toxin	25–300 U BTX-A 0.9% saline	Discomfort at injection place

Table 2. Pharmacotherapy for neuropathic pain(1)**.**

1. **First-line Treatment:**

a. **Gabapentin:** A drug called gabapentin is used to treat specific kinds of pain and seizures. Itprimarily engages in interactions with the α2δ-1 subunit, which is connected to calcium channels in nerve cells. It impedes the movement of some calcium channel units, especially the N-type, within nerve cells in particular body locations via binding to α2δ-1. By doing this, painis lessened and its signalling is diminished. Further disrupting the pathways involved in pain signal transmission, gabapentin also obstructs the regular migration of α2δ-1 subunits between nerve cells(14).

Brand name- *Gralise, Neurontin*

b. **Pregabalin**: In addition to treating fibromyalgia and nerve pain, Pregabalin can also be usedin conjunction with other drugs to treat partial onset seizures.

MOA: By attaching to a particular subunit of calcium canals present in nerve cells—the alpha2- delta subunit—Pregabalin actions on the central nervous system. The discharge of numerous substances that may exacerbate nerve sensitivity is regulated in part by this connection. Its mechanism of action is further complicated by the fact that Pregabalin inhibitsthe alpha2-delta subunit's ability to cross intracellular boundaries. While the arrangement of pregabalin is like to that of gamma-aminobutyric acid, or GABA, a neurotransmitter that reduces neuronal activity, pregabalin does not directly interact with receptors for Brahmi or GABA(15).

Brand Name: *Lyrica*

2. **Second line treatment:**

a. **Tramadol:** One kind of painkiller that acts straight on the central nervous system is this drug. In order to aid individuals with adequate to severe discomfort, it functions as both an opioid, which blocks pain signals, and an SNRI, which increases serotonin and norepinephrinelevels.

MOA: Tramadol is an analgesic that acts on μ-opioid receptors in the central nervous system in addition to serving as an SNRI, which is comparable to serotonin/norepinephrine reuptake inhibitors. It shares mechanical resemblances with both morphine and codeine. It binds to both κ- and δ-opioid receptors inadequately, although it has a far lesser empathy for the μ-opioid receptor than morphine. Alpha2-adrenoreceptors, neurokinin 1 receptors, voltage-gated sodium channels, TRPV1 receptors (also known as the capsaicin receptor), muscarinic receptors (M1 and M3), NMDA receptors (glutamate receptors), Adenosine A1 receptors, and nicotinic acetylcholine receptors are among the pain modulators that are impacted by tramadol(16).

Brand Name: *Conzip, Qdolo, Ralivia, Ryzolt, Tridural, Ultram, Zytram.*

b. **Capsaicin:** You can apply a lotion containing capsaicin to your skin to relieve discomfort. It relieves joint and muscle pain as well as nerve pain brought on by illnesses like post-herpeticneuralgia, a form of pain following shingles.

MOA: It is not thought that capsaicin primarily relieves pain because it also has the ability to reduce substance P, a molecule linked to inflammation. On the other hand, capsaicin reduces the sensitivity of nerve fibres by eliciting a cutaneous response. The nerves' inability to convey specific molecules that influence their behaviour, their temporary incapacitation from normal function, and the temporary retractions of the skin's nerve terminals are the main causes of this shift in how pain is perceived(17).

Brand Name: *Capzasin-HP, Castiva Warming, Lidopro, Medi-derm, Medrox, Qutenza, Rematex, Xoten-C, Zostrix*

3. Third line treatment:

Strong opioids:

a. Morphine: This medicine, an opioid agonist, is intended to assist in the break of moderateto severe pain, whether it be acute or chronic in nature.

MOA: The primary component, morphine-6-glucuronide, is accountable for around 85% of the effects resulting from morphine consumption. The way morphine and its derivatives function in the body is by stimulating the mu and kappa opioid receptors. In specifically, the special effects of morphine on the brain's ventral tegmental region depend on the mu-opioid receptor. Through activating the delta-opioid receptor in the nucleus accumbens, morphine stimulates the reward system. On the other hand, the mu-opioid receptor affects respiratory patterns and the likelihood of addiction(16).

Brand Name: *Arymo, Doloral, Duramorph, M-ediat, M-eslon,*

b. Oxycodone: An opioid such as this medicine is used to assist manage modest to plain pain.

MOA: The precise mechanism of action of oxycodone is unknown. However, some opioid receptors in different places of the body become more responsive to these drugs in settings when there is inflammation or heightened sensitivity to pain. Opioid painkillers include oxycodone and its active forms, such as oxymorphone and noroxycodone. We don't know how these chemicals might be actively carried into the brain, but they can cross the blood-brain barrier to get there. They bind to distinct kinds of opioid receptors in the body and in the central nervous system, which sets off a series of events through a signaling cascade that involves G proteins. Some calcium channels that are involved in the transmission of pain signals become less active when the mu opioid receptors are activated(18).

Brand Name: *Endocet, Nalocet, Oxaydo, Oxy.IR, Percocet, Prolate.*

2. Non-pharmacological Approaches for treatment of neuropathic pain:

1. Clinical Interventional Techniques:

Neuromodulation: The process of modifying nerve activity by delivering a stimulus—such as chemicals or electrical stimulation—to particular brain regions within the body is known as neuromodulation. It entails procedures meant to alter how the neural system functions, frequently in an effort to lessen the symptoms of different neurological or mental illnesses(19).

a. Spinal Cord Stimulation (SCS): A slightly aggressive method called spinal cord stimulation (SCS) is used to manage long-lasting discomfort that has not improved with previous forms of treatment. It entails implanting a tiny gadget that interferes with the brain's ability to receive pain signals by sending electrical impulses into the spinal cord(20).

Mechanism of Action: Peripheral nerves send pain signals to the spinal cord, which carries them to the brain, where the brain interprets them as pain. Through implanted electrodes, moderate electrical impulses are sent to the spinal cord's nerves in order to facilitate spinal cord stimulation. In essence, these electrical impulses block or mask the experience of pain before it reaches the brain by interfering with the transmission of pain signals. Although the precise process by which SCS reduces pain is not entirely known, it is thought toentail intricate relationships between the nervous system and electrical stimulation(21).



Fig 3. Using a device known as a pulse generator, a modest electric current is sent concluded a cable to an conductor positioned in the spine's epidural area as part of the spinal cord stimulation therapy for neuropathic pain. Certain nerve fibres (A fibres) are activated by this electric current, and this can help improve the passage of pain signals (A and C fibres) to the brain. The pain is reduced as a result of this masking effect.

Indications: Those with persistent neuropathic pain disorders who have not improved with alternative therapies are usually candidates for SCS. Diabetes-related neuropathy, complex regional pain syndrome (CRPS), failed back surgery syndrome, and other neuropathic pain types are common indications. While here is tiny data to support its efficacy for these ailments, it may also be taken into consideration for other chronic pain disorders such refractory angina and peripheral vascular disease(22).

Benefits: For several patients suffering from lasting neuropathic pain, stem cell therapy (SCS) can meaningfully decrease pain and enhance quality of life. As a reversible and changeable therapeutic approach, it enables customised therapy to be implemented according to the patient's response. SCS may lessen the need for other pain management techniques including opioid drugs, which may lower the risk of opioid dependence and adverse effects(23).

b. Steroidal Injection and Neural Blockage: Stated differently, neuropathic pain brought on by compression or trauma can be momentarily alleviated by steroid injections around nerves. In order to function, they lessen aberrant nerve activity. Research revealed that these injections worked better than another medicine that relieves pain, lidocaine. While modest pain alleviation has also been demonstrated by epidural steroid injections in the short term, there appears to be no correlation between these injections with a decreased likelihood of surgery. Though their effectiveness is still somewhat unknown, doctors occasionally advise using steroids and local anaesthetics to treat nerve pain caused by disorders including shingles and lower back problems. The fact that nerve blocks and steroid injections can occasionally harm the nerves themselves restricts their usefulness, which is one of the key issues with these procedures. Furthermore, it's not always simple to precisely target the appropriate nerves for blockage. To treat complex regional pain syndromes, another treatment option entails inhibiting the sympathetic ganglia, though it's yet unknown how much long-term comfort this offers(24).



Fig 4. Epidural Injection Administration

c. **Transcranial and Epidural Stimulation:** Simplified, transcranial magnetic stimulation (TMS) is a technique that stimulates neural tissues such as the cerebral cortex, spinal nerve roots, and cranial nerves by means of magnetic fields. Michael Faraday, a physicist, developed electromagnetic induction in 1838, and this discovery serves as the foundation for TMS. In order to stimulate nerve cells, a specific coil is applied to the scalp close to the head during a TMS session. The coil emits short magnetic pulses. One can deliver these pulses as a single stimulus or repeat them at various frequencies and intervals. According to research, delivering repetitive magnetic stimulation—particularly at 10 Hz—to the motor area of the brain may help reduce the indications of persistent neuropathic discomfort. Dopamine release in the brain's motor cortex, which aids in controlling pain pathways, may be connected to this pain relief. Though its precise mechanism of action for pain relief from recurrent magnetic stimulation is still unknown(22).



Fig. 5 Transcranial Magnetic Stimulation

Put more simply, two basic strategies for repetitive transcranial magnetic stimulation (rTMS) have been recently brought to light. A technique known as "theta-burst" stimulation combines high-frequency, low-intensity, short-duration repetitive thermomechanical stimulation (rTMS). Using straight use of inadequately negative or continuously positive currents to the scalp, the other method modifies brain impulses(25). According to a recent study,

resistant central neuropathic pain can be reduced over the course of three weeks with four consecutive rTMS sessions employing electromagnetic induction at 20 Hz on the main motor cortex. This implies that TMS might be a decent substitute for handling neuropathic discomfort. The fact that these methods work with portable devices makes them even more practical(26).



Fig. 6 Epidural electrical stimulation

In other words, because of possible hazards, certain individuals should not undergo transcranial magnetic stimulation (TMS). Examples of these patients include those with deep brain electrodes, aneurysm clips, cochlear implants, cardiac pacemakers, or a past of epilepsy. In instances where existing treatments are ineffective, alternative therapies such as epidural motor cortex stimulation (EMCS) and transcranial direct current stimulation (tDCS) have been proposed. Research indicates that EMCS can offer substantial pain alleviation (more than 40%) for roughly 60-65% of patients, whereas tDCS has demonstrated advantages for a variety of peripheral neuropathies. “The motor cortex region is carefully targeted by a stimulating electrode in EMCS. The European recommendations propose tDCS as a treatment for peripheral neuropathic pain, and for persistent neuropathic pain that does not reply to other treatments, rTMS and EMCS should be taken into consideration(27).

Deep Brain Stimulation (DBS): Put more simply, there is continuous discussion on the efficiency of prolonged intracranial stimulation in the treatment of neuropathic discomfort. In an effort to reduce pain perception, researchers have looked into the use of Deep Brain Stimulation (DBS), which targets the motor cortex, nucleus accumbens, sensory thalamus, internal capsule, periaqueductal/periventricular grey, septum, anterior cingulate cortex, and posterior hypothalamus. Although the National Institute for Health and Care Excellence (NICE) in the United Kingdom recommends DBS for patients who are refractory, new research indicates that there are serious dangers involved with the treatment. These dangers include seizures during surgery, implanted lead fractures, and wound infections. On the other hand, there is conflicting advice from European guidelines when it comes to using DBS to treat neuropathic pain(28).



Fig. 7 Deep Brain Stimulation

d. **Percutaneous Neuromodulation Therapy (PENS):** Percutaneous Neuromodulation Therapy (PENS) is a new, slightly aggressive method for pain reduction, to put it simply. By putting small, disposable needle-like probes into the skin to start sensory nerves in regions where neuropathic pain occurs, it combines components of electrical nerve stimulation, transcutaneous electrical nerve stimulation (TENS), and electro acupuncture(29).

Due to limits in nerve conduction, PENS is thought to be a better alternative for patients who have not had relief via electro acupuncture or transcranial electrical nerve stimulation. The method by which PENS stimulates sensory nerves close to the painful area with an electrical current is appropriately referred to as "percutaneous neuromodulation therapy"; tiny needle probes are inserted just beneath the skin. Typically, PENS treatment consists of eight to ten thirty-minute sessions held one time or double a week(30).

It's thought that electrical stimulation interrupts pain impulses and causes the brain's natural pain-relieving chemicals, such as serotonin and endorphins, to be released. Although the precise mechanism by which PENS lowers pain is not entirely understood. PENS has been shown to be especially beneficial in the short term, enhancing patients' mood, functionality, and excellence of sleep. It can help with a diversity of pain situations, but its purpose is not to replace conventional painkillers; rather, it is to supplement them, possibly lowering the need for larger dosages of prescription(31).

e. **Transcutaneous Electrical Nerve Stimulation:** Neuropathy is frequently treated with transcutaneous electrical nerve stimulation (TENS), a non-invasive procedure. This is a summary of TENS's operation and how it's used to treat neuropathic pain. TENS uses electrodes applied to the skin close to the painful location to deliver tiny electrical pulses. By stimulating sensory nerves with these electrical pulses, pain signals that are sent to the brain can be lessened. Additionally, the sensation of tingling or massaging may serve as a diversion from the pain. Neuralgia (pain after shingles), diabetic neuropathy, peripheral neuropathy, and pain associated to damage or compression of the nerves are among the neuropathic pain syndromes that are commonly treated with TENS. Burning, tingling, or shooting pain are examples of aberrant signalling and sensations associated with neuropathic pain, which results from injury or dysfunction of the nerves. In order to alleviate pain, TENS attempts to modify these aberrant pain signals(32)(33).

2. **Gene Therapy against Neuropathic Pain:** A method called "gene therapy" was developed roughly thirty years ago to fix damaged genes. It attains this by either adding genes to offset the disease-causing effects of faulty ones or replacing them with healthy ones. With the use of this technique, the body produces more of certain proteins—such as receptors, ion channels, neurotransmitters, and biochemical mediators—which are essential for preserving physiological conditions. Since gene therapy tackles the genetic causes of diseases rather than just their symptoms, it may be more effective than traditional pharmaceutical treatments in treating certain disorders. Because gene therapy targets the precise problem location and is less prone to cause tolerance, it also decreases undesired side effects. It can also be utilised in conjunction with conventional therapeutic approaches. Prior to the development of gene therapy, only medication provided access to certain treatment options. Research in this area is still in progress, although numerous potential strategies have already been shown. Spinal opioid gene therapy and anti-inflammatory cytokine gene therapy are two important biological targets in pain management gene therapy(34)(35).



Fig. 8 Gene Therapy in Opposition to Neuropathic Pain

3. **Spinal Opioid Gene Therapy:** Gene therapy is showing interest in the opioid systems as a result of the growing usage of opioid-based medications to treat neuropathic pain. Pain treatment has been achieved by intrathecal delivery of opioids, which delivers the drug straight into the spinal cord. Consequently, to lessen chronic pain, a particular opioid gene is inserted into the dorsal root ganglion (DRG) by a vector known as recombinant adeno-associated virus (AAV) in preclinical research. The main sensory neurons of the rats are injected with this vector, which contains complementary opioid receptor DNA. Pain alleviation that lasts for up to six months is the outcome of this increasing the number of opioid receptors in the DRG. These methods haven't been used on humans yet; they're still in preclinical studies. Two major approaches that have been developed from spinal opioid gene therapy have demonstrated promise in preclinical animals for causing pain alleviation in neuropathy. In combination with conventional pain management, one method entails injecting a herpes simplex virus (HSV) vector with genes that modulate pain directly into skin sensory neurons. Giving opioid receptor-encoding genes is the other strategy. In some rodent models of neuropathic and inflammatory discomfort, both of these methods have been effective in lowering hyperalgesia and mechanical allodynia. With this advancement, the negative consequences of externally delivered opioids—like side effects in peripheral tissues and the central nervous system— might be eliminated(36)(37)(38).

4. **Ion Channel Targeting:** Since ion channels are well known to be involved in pain transmission and signalling, treating conditions such as chronic neuropathic pain primarily targets them. The resting membrane potential is regulated by leak channels and voltage-gated channels. Ion channels may become hyper responsive due to injury, inflammation, or nerve lesions, which can result in uncontrollably high neuronal activity. These ion channels may be modulated to potentially relieve pain. The recent advancements in several ion channels that cause sensory fibre hyper excitability and are showing promise as therapeutic targets for pain are the main topic of this review. Furthermore, several venom peptides are being investigated for their potential to alter ion channels, which could one day provide a potent treatment for complicated neurological conditions. Neuropathic pain is thought to arise and persist due to dysregulation of ion channels. Anomalous pain signalling, hyperactivity of pain pathways in the nervous system, and modified neuronal excitability can all result from modifications in ion channel expression, distribution, or activity. Ion channel targeting is a potentially effective therapeutic strategy for managing neuropathic pain since it provides a means of modifying the nervous system's pain signalling pathways and neuronal excitability. Researchers want to reduce side effects and enhance patient outcomes by developing more precise and focused treatments for neuropathic pain by specifically targeting ion channels involved in pain processing(39)(40)(41)**.**

7. Precision Medicine in Neuropathic Pain:

A medical strategy to treating patients that involves customizing therapy to each patient's unique needs is called precision medicine, sometimes referred to as customized medicine. To maximize the results of treatment, this method takes into account variables in genetics, lifestyle, environment, and other pertinent information. Precision medicine offers more focused and efficient treatments that have the possible to completely transform the treatment of neuropathic pain. Known for being notoriously difficult to treat with traditional painkillers, neuropathic pain is a complex illness resultant after damage or dysfunction of the nerve system(42).

1. **Genetic Factors:**

a. **Genetic Testing:** Genetic differences can affect a person's sensitivity to neuropathic pain as well as how they react to painkillers. Treatment choices can be influenced by the identification of particular gene mutations or variants found through genetic testing and linked to neuropathic pain problems. An individual's reaction to pain and painkillers can be greatly influenced by hereditary variables. Healthcare professionals can determine genetic differences that could affect a patient's susceptibility to neuropathic pain or how they react to particular drugs by examining the patient's genetic composition. Differences in the genetic factor that encrypt drug carriers or drug-metabolizing enzymes, for instance, may affect a patient's reaction to specific neuropathic pain treatments(43).

b. **Pharmacogenomics:** The anatomical and functional alterations in the brain and peripheral nervous system linked to neuropathic pain can be better understood with the usage of innovative imaging methods like magnetic resonance imaging (MRI) and functional MRI (fMRI). Targeted treatments, including neuromodulation therapies, can be developed with the use of neuroimaging, which can help identify specific brain pathways involved in pain processing(44).

8. Molecular Factors:

c. **Biomarker Analysis:** Measurable markers of biological reactions to illness or processes are known as biomarkers. It is possible to forecast the sequence of the illness, the effectiveness of management, and the discovery of novel therapeutic targets by identifying biomarkers linked to neuropathic pain. Measuring the concentrations of neurotransmitters, neuronal growth factors, and inflammatory markers in blood or cerebrospinal fluid are examples of biomarker analysis(45).

d. **Neuroimaging:** Innovative imaging modalities, like functional magnetic resonance imaging (fMRI) and magnetic resonance imaging (MRI), can shed light on the anatomical and practical alterations in the brain and peripheral nerve system linked to neuropathic pain. Utilizing neuroimaging, targeted therapies like neuromodulation therapies can be developed by identifying certain brain circuits involved in the processing of pain(4).

2. **Psychosocial Factors:**

a. **Psychosocial Assessment**: Psychological comorbidities like sadness, anxiety, and reduced quality of life are frequently present in conjunction with neuropathic pain. It is likely to recognise patients who are at danger of not getting the best treatment outcomes and adjust interventions by using standardized questionnaires and interviews to assess psychosocial aspects(46).

b. **Cognitive-Behavioural Therapy (CBT):** Through the modification of maladaptive ideas and behaviours, the development of coping mechanisms, and the improvement of pain management abilities, patients can benefit from cognitive behavioural therapy. Treatment adherence and efficacy can be improved by tailoring CBT sessions to each patient's requirements and preferences(47).

c. **Social Support:** When it comes to managing chronic pain, social support systems are essential. Patients' general well-being and treatment outcomes can be enhanced by enrolling them in support groups, incorporating family members in the planning of their care, and putting them in touch with local resources(47)(48).

9. Recent Developments in Biomarker Identification and Their Potential Clinical Implications:

1. **Identification of Peripheral and Central Biomarkers:** Numerous biomarkers, including neurotrophic factors, neurotransmitters, and inflammatory cytokines, have been linked by researchers to neuropathic pain. Tissues, cerebrospinal fluid, or blood can all include these indicators. Relevance for clinical practice: Neuropathic pain may be objectively diagnosed, illness severity can be evaluated, and therapy response can be tracked with the help of biomarkers(49)**.**

a. **Genetic Biomarkers:** Genetic variations linked to treatment responsiveness and vulnerability to neuropathic pain have been identified thanks to advancements in genomic technologies. Multiple genetic loci associated with pain perception and medicine metabolism have been found through candidate gene techniques and genome-wide association studies (GWAS). Clinical ramifications A person's sensitivity to painkillers, including their effectiveness and likelihood of side effects, can be predicted in part by genetic indicators(50).

b. **Neuroimaging Biomarkers:** Functional MRI (fMRI), diffusion tensor imaging (DTI), and positron emission tomography (PET) are examples of structural and functional neuroimaging techniques that have shed light on the brain underpinnings of neuropathic pain. Changes in the structure, connection, and activity of the brain linked to pain processing are shown by these imaging indicators. Implications for clinical practice: Neuroimaging biomarkers can be used to predict treatment outcomes, locate pain sources, and pinpoint central sensitization mechanisms(51).

c. **Multi-omic Approaches:** One can obtain a thorough evaluation of the molecular processes behind neuropathic pain by combining information from genomes, transcriptomics, proteomics, and metabolomics. Molecular signatures linked to disease development, pain subtypes, and treatment results can be found by multi-omic analysis. Clinical ramifications an insight of the Etiology of neuropathic pain and individual variability can be obtained through the use of multi-omic techniques. By discovering new therapeutic targets and forecasting reactions to current therapies, they could aid in the creation of precision medicine tactics(52).

d. **Patient -reported Outcome Measures:** Apart from biomarkers, patient-reported outcome measures (PROMs) record subjective feelings related to pain, functional disability, and excellence of life. To measure pain strength, interference, and emotional well-being, PROMs include validated questionnaires, visual analogue scales, and electronic diaries. Applications in medicine: PROMs offer important information on the patient's viewpoint, therapeutic objectives, and efficacy of treatment. Patient-centred care is facilitated, collaborative decision- making is made easier, and patient-provider communication is enhancedwhen PROMs are successfully incorporated into clinical practice(53).

10. Digital Health Solution:

Neuropathic pain is a complicated and frequently incapacitating ailment that presents many difficulties for both sufferers and medical professionals. Digital technologies, however, have shown promise as tools to help control neuropathic pain. This investigation aims to investigate how different digital technologies, such as wearables, telemedicine, and mobile apps, might be used to manage neuropathic pain. Digital technologies are essential in the treatment of neuropathic pain because they give patients self-monitoring tools, educational resources, and remote access to medical services. These skills have the potential to expand outcomes and improve the excellence of lifetime for persons with neuropathic pain as they develop further and become more integrated with conventional care practices. To optimise the advantages of digital pain treatment systems, however, issues including data privacy, legal compliance, and unequal access to technology need to be addressed(54)(55).

11. Challenges and Future Directions:

1. **Treatment Resistance:** Many people with neuropathic pain may not get enough relief from traditional treatments such analgesics, antidepressants, and anticonvulsants. Neuropathic pain is a particularly challenging condition to treat. Neuropathic pain syndrome heterogeneity, individual differences in treatment responsiveness, and the intricate underlying mechanisms of neuropathic pain can all lead to treatment resistance. So, in order to obtain adequate pain management, certain patients would need interdisciplinary approaches that include pharmaceutical, interventional, and non-pharmacological treatments(56).
2. **Limited Efficacy of Available Treatment:** While a number of drugs are frequently used to treat neuropathic pain, their effectiveness is frequently restricted, and they may have unfavourable side effects. For instance, although being given often for neuropathic pain, opioids have little proof of their effectiveness and come with a risk of addiction, tolerance, and overdose. Similarly, while some individuals may benefit from antidepressants and anticonvulsants, side effects such sleepiness, weight gain, and cognitive impairment are possible(57).
3. **Psychological Comorbidities:** Sleep problems, anxiety, sadness, and a lower quality of life are among the psychosocial comorbidities that are frequently linked to neuropathic discomfort. Comorbidities have the potential to worsen pain symptoms and make treatment decisions more difficult. A thorough, biopsychosocial approach to pain management is necessary to address psychosocial issues. This approach should include social support, psychiatric interventions, and lifestyle changes(58).
4. **Limited Accessibility to Specialised Care:** It may be difficult to access specialty providers, multidisciplinary pain programmes, pain clinics, and other specialised pain management services, especially in underserved or rural locations. Geographical obstacles, inadequate healthcare facilities, labour shortages, and budgetary restraints are some of the factors causing limited accessibility. Many people with neuropathic pain may thus experience discrepancies in access to evidence-based care, poor treatment options, and delays in diagnosis(59).
5. **Stigma and Misconceptions:** Healthcare professionals, members of the general public, and even some people who experience chronic pain themselves frequently lack adequate understanding of neuropathic pain. Misconceptions, scepticism, and stigma surrounding the validity of neuropathic pain can cause patients' experiences to be discounted, undertreated, and delayed in receiving the proper care. In order to dispel stigma, increase empathy, and develop a more compassionate attitude towards pain management, education and awareness-raising campaigns are necessary(60).

12. Conclusion:

The limited therapy choices for neuropathic pain provide a considerable barrier for both patients and professionals. Patients find it less appealing to get current medicines since they frequently have serious adverse effects. Nonetheless, a few interventional techniques, such as spinal cord stimulation, have demonstrated potential for successful pain relief. By affecting the cortical areas of the brain, transcranial magnetic stimulation (TMS) has also shown promise in treating related diseases and lowering pain. Furthermore, novel approaches that target particular ion channels, ontogenetic, chemo genetics, gene therapy, and Percutaneous Electrical Nerve Stimulation (PENS) have demonstrated promise in the management of neuropathic discomfort. Notwithstanding these developments, a lot of these techniques are still in the early phases of investigation and may encounter difficulties when moving to clinical trials, mostly because of constraints in the existing animal models. Research into these interventional techniques is still ongoing, and it may lead to the growth of innovative treatments that increase the excellence of lifetime for those with neuropathic discomfort. Given the drawbacks and adverse consequences of conventional pharmaceutical therapies, neuromodulation—which encompasses techniques other than nerve signal blockade—is becoming more widely acknowledged as a cutting-edge strategy. Prospectively, multimodal processes and treatments that provide long-term benefits

without developing tolerance will be key components of neuropathic pain management in the future. Investigating and developing these cutting-edge methods is essential to provide patients efficient and long-lasting treatment as the prevalence of neuropathic pain keeps rising.

12. References:

1. Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33.
2. Couto DS, Goulart G, Luciano LL, Cardoso EJR. Quality of life in neuropathic pain: a literature review. Res Soc Dev. 2021;10(14):e416101422250.
3. Kumar A, Pottabathini R, Bhatnagar A, Garg S, Gupta V. Pharmacological management of neuropathic pain: Current trends and possible approaches. Arch Neurosci. 2017;4(1):1–13.
4. Cohen SP, Mao J. Neuropathic pain: Mechanisms and their clinical implications. BMJ. 2014;348:1–12.
5. Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol [Internet]. 2010;9(8):807–19. Available from: http://dx.doi.org/10.1016/S1474-4422(10)70143-5
6. Ferraro F, Jacopetti M, Spallone V, Padua L, Traballesi M, Brunelli S, et al. Diagnosis and treatment of pain in plexopathy, radiculopathy, peripheral neuropathy and phantom limb pain: Evidence and recommendations from the Italian Consensus Conference on Pain on Neurorehabilitation. Eur J Phys Rehabil Med. 2016;52(6):855–66.
7. Harden RN. Chronic neuropathic pain: Mechanisms, diagnosis, and treatment. Neurologist. 2005;11(2):111–22.
8. Meacham K, Shepherd A, Mohapatra DP, Haroutounian S. Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr Pain Headache Rep. 2017;21(6).
9. Krames ES. The dorsal root ganglion in chronic pain and as a target for neuromodulation: A review. Neuromodulation. 2015;18(1):24–32.
10. Vranken JH. Vranken_mechanism-treatment-neuropathic-pain.pdf. 2009. p. 71–8.
11. Chang KH, Ro LS. Neuropathic pain: Mechanisms and treatments. Chang Gung Med J [Internet]. 2005;28(9):597–605. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N& AN=41634706
12. James CF. Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update. SiSli Etfal Hastan Tip Bul / Med Bull Sisli Hosp. 2022;56(1):1–20.
13. Rugnath R, Orzechowicz C, Newell C, Carullo V, Rugnath A. A Literature Review: The Mechanisms and Treatment of Neuropathic Pain—A Brief Discussion. Biomedicines. 2024;12(1):1–12.
14. Version of Record: https://www.sciencedirect.com/science/article/pii/S0035378718307276. 2018;1–14.
15. Verma V, Singh N, Singh Jaggi A. Send Orders for Reprints to reprints@benthamscience.net Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms. Curr Neuropharmacol. 2014;12:44–56.
16. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83(3):389–400.
17. Afonso AS, Carnaval T, Cés SV. Combination therapy for neuropathic pain: A review of recent evidence. J Clin Med. 2021;10(16):1023–34.
18. Balanaser M, Carley M, Baron R, Finnerup NB, Moore RA, Rowbotham MC, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults: Systematic review and meta-analysis. Pain. 2023;164(2):230–51.
19. Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth [Internet]. 2023;131(1):79–92. Available from: https://doi.org/10.1016/j.bja.2023.04.021
20. Schlereth T. Guideline "diagnosis and non interventional therapy of neuropathic pain" of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2(1).
21. Alorfi NM. Pharmacological Methods of Pain Management: Narrative Review of Medication Used. Int J Gen Med. 2023;Volume 16:3247–56.
22. Qureshi AR, Jamal MK, Rahman E, Paul DA, Oghli YS, Mulaffer MT, et al. Non- pharmacological therapies for pain management in Parkinson's disease: A systematic review. Acta Neurol Scand. 2021;144(2):115–31.
23. Burkey AR, Chen J, Argoff CE, Edgar DR, Petersen EA. Painful Peripheral Neuropathies of the Lower Limbs and/or Lower Extremities Treated with Spinal Cord Stimulation: A Systematic Review with Narrative Synthesis. J Pain Res. 2023;16(May):1607–36.
24. Meyer HP. Neuropathic pain - Current concepts. South African Fam Pract. 2008;50(3):40–9.

25. Version of Record: https://www.sciencedirect.com/science/article/pii/S1388245721006106. 2021;
26. Jiang X, Yan W, Wan R, Lin Y, Zhu X, Song G, et al. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132(November):130–41.
27. Seddighi AS, Seddighi A, Ghadirian M, Zali A, Tabatabaei Far SM. Neuropathic Pain: Mechanism, Representation, Management and Treatment. Int Clin Neurosci J. 2022;9(1):e18–e18.
28. Nguyen JP, Nizard J, Keravel Y, Lefaucheur JP. Invasive brain stimulation for the treatment of neuropathic pain. Nat Rev Neurol [Internet]. 2011;7(12):699–709. Available from: http://dx.doi.org/10.1038/nrneurol.2011.138
29. Rossi M, de Carolis G, Liberatoscioli G, Iemma D, Nosella P, Nardi LF. A novel mini- invasive approach to the treatment of neuropathic pain: The PENS study. Pain Physician. 2016;19(1):E121–8.
30. Pain PN, Johnson S. Assessment of Low-Frequency Nerve Stimulation for in philosophy by. 2022;(January).
31. Mohiuddin AK. Non-Drug Pain Management: Opportunities to Explore [Internet]. 2019. 42 p. Available from: https://biomedgrid.com/ebooks/non-drug-pain- management-opportunities-to-explore.pdf
32. Mokhtari T, Ren Q, Li N, Wang F, Bi Y, Hu L. Transcutaneous Electrical Nerve Stimulation in Relieving Neuropathic Pain: Basic Mechanisms and Clinical Applications. Curr Pain Headache Rep. 2020;24(4).
33. Johnson MI, Bjordal JM. Transcutaneous electrical nerve stimulation for the management of painful conditions: Focus on neuropathic pain. Expert Rev Neurother. 2011;11(5):735–53.
34. James SR, Chidiac EJ. Gene Therapy for Chronic Neuropathic Pain : How Does It Work and Where Do We Stand Today ? 2011;808–22.
35. Pessoa BL, Escudeiro G, Nascimento OJM. Emerging Treatments for Neuropathic Pain. Curr Pain Headache Rep. 2015;19(12):1–9.
36. Siniscalco D, Novellis V, Rossi F, Maione S. Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy? Curr Drug Targets. 2005;6(1):75–80.
37. Attal N, Bouhassira D. Advances in the treatment of neuropathic pain. Curr Opin Neurol. 2021;34(5):631–7.
38. Guedon JMG, Wu S, Zheng X, Churchill CC, Glorioso JC, Liu CH, et al. Current gene therapy using viral vectors for chronic pain. Mol Pain. 2015;11(1):1–23.
39. Gangadhar M, Mishra R, Sriram D, Yogeeswari P. Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets. CNS Neurol Disord - Drug Targets. 2014;13(1):63–81.
40. Eglen RM, Hunter JC, Dray A. Ions in the fire: Recent ion-channel research and approaches to pain therapy. Trends Pharmacol Sci. 1999;20(8):337–42.
41. Birch PJ, Dekker L V., James IF, Southan A, Cronk D. Strategies to identify ion channel modulators: Current and novel approaches to target neuropathic pain. Drug Discov Today. 2004;9(9):410–8.
42. Chadwick A, Frazier A, Khan TW, Young E. Understanding the psychological, physiological, and genetic factors affecting precision pain medicine: A narrative review. J Pain Res. 2021;14:3145–61.
43. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact, and risk factors. Vol. 161, Pain. 2020. 127–137 p.
44. Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, et al. Update on the pharmacogenomics of pain management. Pharmgenomics Pers Med. 2019;12:125– 43.
45. Calvo M, Davies AJ, Hébert HL, Weir GA, Chesler EJ, Finnerup NB, et al. The Genetics of Neuropathic Pain from Model Organisms to Clinical Application. Neuron. 2019;104(4):637–53.
46. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet [Internet]. 2021;397(10289):2082–97. Available from: http://dx.doi.org/10.1016/S0140-6736(21)00393-7
47. warwick.ac.uk/lib-publications. 2017;
48. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The Biopsychosocial Approach to Chronic Pain: Scientific Advances and Future Directions. Psychol Bull. 2007;133(4):581–624.
49. Gunn J, Hill MM, Cotten BM, Deer TR. Observational Study An Analysis of Biomarkers in Patients with Chronic Pain. Pain Physician [Internet]. 2020;23:e41–9. Available from: www.painphysicianjournal.com
50. Marchi A, Vellucci R, Mameli S, Piredda AR, Finco G. Pain biomarkers. Clin Drug Investig. 2009;29(SUPPL. 1):41–6.

51. Duarte FCK, West DWD, Linde LD, Hassan S, Kumbhare DA. Re-Examining Myofascial Pain Syndrome: Toward Biomarker Development and Mechanism-Based Diagnostic Criteria. Curr Rheumatol Rep. 2021;23(8).

52. Shin A, Kashyap PC. Multi-omics for biomarker approaches in the diagnostic evaluation and management of abdominal pain and irritable bowel syndrome: what lies ahead. Vol. 15, Gut Microbes. 2023.

53. Chaturvedi P, Khan R, Sahu P, Ludhiadch A, Singh G, Munshi A. Role of Omics in Migraine Research and Management: A Narrative Review. Mol Neurobiol [Internet]. 2022;59(9):5809–34. Available from: https://doi.org/10.1007/s12035-022-02930-3

54. 2023- thesis- metabilomicas and oxidative stress in OA non responders- new foundland. 2023;(October).

55. Steensberg A, Simons TD. Beyond biomarkers in drug discovery and development. Drug Discov Today. 2015;20(3):289–91.

56. Al-Harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer Adherence [Internet]. 2012;6(May):369–88. Available from: https://doi.org/10.2147/PPA.S29716

57. Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: Current perspective and future directions. Pharmacol Res. 2014;80:21–35.

58. Liu MG, Chen J. Preclinical research on pain comorbidity with affective disorders and cognitive deficits: Challenges and perspectives. Prog Neurobiol [Internet]. 2014;116(January 2014):13–32. Available from: http://dx.doi.org/10.1016/j.pneurobio.2014.01.003

59. Chaboyer W, James H, Kendall M. Transitional Care After the Intensive Care Unit. Crit Care Nurse. 2005;25(3):16–28.

60. Reynolds CF, Jeste D V., Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry. 2022;21(3):336–63.